An investigational extended-release (ER) formulation of amantadine hydrochloride (ADS-5102, Adamas Pharmaceuticals) led to a statistically significant reduction in levodopa-induced dyskinesia (LID) ...
PharmaTher Holdings Ltd. PHRRF PHRM, a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in ...
NJ, UNITED STATES, March 20, 2023 /EINPresswire.com/ -- Neurolixis, Inc., a private, clinical-stage company developing innovative drug therapies for the treatment of ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...
FDA clears path for Phase 3 testing following positive Type B meeting Regulatory alignment confirms preclinical data sufficient for pivotal ...
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today announced the launch of ...
SAN DIEGO--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, announced today that ...
Oral levodopa is the gold standard treatment for motor symptoms in individuals diagnosed with Parkinson’s disease, despite the risk of dyskinesia (sudden uncontrolled movements) related to long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback